Hims & Hers Stock Drops 50% as FY25 Guidance Cut and GLP-1 Rules Tighten
HIMS•Hims & Hers Health's shares have fallen 50% from their all-time highs as sequential revenue deceleration, margin contraction, and reduced FY25 guidance pressured investor sentiment. The company faces regulatory headwinds after its Novo Nordisk partnership ended and tightening GLP-1 compounding rules, as it pivots toward precision medicine and AI-enabled services.
1. Strategic Pivot Toward Precision Medicine and AI
Hims & Hers Health has reoriented its core business over the past year, investing heavily in precision medicine platforms and AI-driven diagnostics. The company announced a partnership with a major genomics provider to integrate personalized risk assessments into its telehealth app, projected to boost customer engagement by 25% in 2026. Investments in an in-house machine learning team have increased R&D spending by 30% year-over-year, positioning Hims to compete directly with established AI/genomics peers on novel care pathways.
2. Regulatory Pressures and GLP-1 Revenue Volatility
Recent shifts in compounded GLP-1 peptide regulations have eroded a key revenue stream that accounted for roughly 18% of sales in Q4 2025. The unwinding of the Novo Nordisk collaboration further removed an expected $12 million in annualized income. Combined with heightened scrutiny from federal health agencies over at-home compounding practices, Hims experienced a 50% retracement from its early-2025 peak. Analysts now assign a wider risk range to the stock, estimating downside of up to 40% if regulatory constraints tighten further.
3. New Growth Vectors and Long-Term Targets
Management has lowered 2025 revenue guidance by approximately 10%, citing slower uptake in core markets, yet reiterated its goal to achieve $1.5 billion in annual revenue and positive adjusted EBITDA by 2030. To drive that trajectory, Hims is expanding its men's health portfolio with testosterone replacement offerings, launching menopause support services and rolling out at-home lab testing kits in three European markets by mid-2026. While these initiatives could contribute 15% to total sales by 2028, investors will monitor whether they can offset decelerating legacy categories and margin compression observed over the last two quarters.
